Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Breast Cancer | Research

Automated breast volume scanner based Radiomics for non-invasively prediction of lymphovascular invasion status in breast cancer

Authors: Yue Li, Xiaomin Wu, Yueqiong Yan, Ping Zhou

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Purpose

Lymphovascular invasion (LVI) indicates resistance to preoperative adjuvant chemotherapy and a poor prognosis and can only be diagnosed by postoperative pathological examinations in breast cancer. Thus, a technique for preoperative diagnosis of LVI is urgently needed. We aim to explore the ability of an automated breast volume scanner (ABVS)-based radiomics model to noninvasively predict the LVI status in breast cancer.

Methods

We conducted a retrospective analysis of data from 335 patients diagnosed with T1-3 breast cancer between October 2019 and September 2022. The patients were divided into training cohort and validation cohort with a ratio of 7:3. For each patient, 5901 radiomics features were extracted from ABVS images. Feature selection was performed using LASSO method. We created machine learning models for different feature sets with support vector machine algorithm to predict LVI. And significant clinicopathologic factors were identified by univariate and multivariate logistic regression to combine with three radiomics signatures as to develop a fusion model.

Results

The three SVM-based prediction models, demonstrated relatively high efficacy in identifying LVI of breast cancer, with AUCs of 79.00%, 80.00% and 79.40% and an accuracy of 71.00%, 80.00% and 75.00% in the validation cohort for AP, SP and CP plane image. The fusion model achieved the highest AUC of 87.90% and an accuracy of 85.00% in the validation cohort.

Conclusions

The combination of radiomics features from ABVS images and an SVM prediction model showed promising performance for preoperative noninvasive prediction of LVI in breast cancer.
Literature
1.
go back to reference Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer Dove Med Press. 2019;11:151–64.PubMedPubMedCentral Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer Dove Med Press. 2019;11:151–64.PubMedPubMedCentral
2.
go back to reference Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33.CrossRefPubMed Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33.CrossRefPubMed
3.
go back to reference Kozłowski J, Kozłowska A, Kocki J. Breast cancer metastasis - insight into selected molecular mechanisms of the phenomenon. Postepy Hig Med Doswiadczalnej Online. 2015;69:447–51.CrossRef Kozłowski J, Kozłowska A, Kocki J. Breast cancer metastasis - insight into selected molecular mechanisms of the phenomenon. Postepy Hig Med Doswiadczalnej Online. 2015;69:447–51.CrossRef
6.
go back to reference Sleeman JP, Thiele W. Tumor metastasis and the lymphatic vasculature. Int J Cancer. 2009;125:2747–56.CrossRefPubMed Sleeman JP, Thiele W. Tumor metastasis and the lymphatic vasculature. Int J Cancer. 2009;125:2747–56.CrossRefPubMed
7.
go back to reference Rakha EA, Martin S, Lee AHS, Morgan D, Pharoah PDP, Hodi Z, et al. The prognostic significance of lymphovascular invasion in invasive breast carcinoma. Cancer. 2012;118:3670–80.CrossRefPubMed Rakha EA, Martin S, Lee AHS, Morgan D, Pharoah PDP, Hodi Z, et al. The prognostic significance of lymphovascular invasion in invasive breast carcinoma. Cancer. 2012;118:3670–80.CrossRefPubMed
8.
go back to reference Ryu YJ, Kang SJ, Cho JS, Yoon JH, Park MH. Lymphovascular invasion can be better than pathologic complete response to predict prognosis in breast cancer treated with neoadjuvant chemotherapy. Med (Baltim). 2018;97:e11647.CrossRef Ryu YJ, Kang SJ, Cho JS, Yoon JH, Park MH. Lymphovascular invasion can be better than pathologic complete response to predict prognosis in breast cancer treated with neoadjuvant chemotherapy. Med (Baltim). 2018;97:e11647.CrossRef
9.
go back to reference K B, N B, A G, V V, A M. Predicting cancer outcomes with radiomics and artificial intelligence in radiology. Nat Rev Clin Oncol. 2022;19. K B, N B, A G, V V, A M. Predicting cancer outcomes with radiomics and artificial intelligence in radiology. Nat Rev Clin Oncol. 2022;19.
10.
go back to reference Lambin P, Leijenaar RTH, Deist TM, Peerlings J, de Jong EEC, van Timmeren J, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14:749–62.CrossRefPubMed Lambin P, Leijenaar RTH, Deist TM, Peerlings J, de Jong EEC, van Timmeren J, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14:749–62.CrossRefPubMed
11.
go back to reference Liu Z, Feng B, Li C, Chen Y, Chen Q, Li X, et al. Preoperative prediction of lymphovascular invasion in invasive breast cancer with dynamic contrast-enhanced-MRI-based radiomics. J Magn Reson Imaging JMRI. 2019;50:847–57.CrossRefPubMed Liu Z, Feng B, Li C, Chen Y, Chen Q, Li X, et al. Preoperative prediction of lymphovascular invasion in invasive breast cancer with dynamic contrast-enhanced-MRI-based radiomics. J Magn Reson Imaging JMRI. 2019;50:847–57.CrossRefPubMed
12.
go back to reference Feng B, Liu Z, Liu Y, Chen Y, Zhou H, Cui E, et al. Predicting lymphovascular invasion in clinically node-negative breast cancer detected by abbreviated magnetic resonance imaging: transfer learning vs. radiomics. Front Oncol. 2022;12:890659.CrossRefPubMedPubMedCentral Feng B, Liu Z, Liu Y, Chen Y, Zhou H, Cui E, et al. Predicting lymphovascular invasion in clinically node-negative breast cancer detected by abbreviated magnetic resonance imaging: transfer learning vs. radiomics. Front Oncol. 2022;12:890659.CrossRefPubMedPubMedCentral
13.
go back to reference Kayadibi Y, Kocak B, Ucar N, Akan YN, Yildirim E, Bektas S. MRI radiomics of breast Cancer: machine learning-based prediction of Lymphovascular Invasion Status. Acad Radiol. 2022;29(Suppl 1):126–34.CrossRef Kayadibi Y, Kocak B, Ucar N, Akan YN, Yildirim E, Bektas S. MRI radiomics of breast Cancer: machine learning-based prediction of Lymphovascular Invasion Status. Acad Radiol. 2022;29(Suppl 1):126–34.CrossRef
14.
go back to reference Guo Y, Hu Y, Qiao M, Wang Y, Yu J, Li J, et al. Radiomics Analysis on Ultrasound for Prediction of Biologic behavior in breast invasive Ductal Carcinoma. Clin Breast Cancer. 2018;18:e335–44.CrossRefPubMed Guo Y, Hu Y, Qiao M, Wang Y, Yu J, Li J, et al. Radiomics Analysis on Ultrasound for Prediction of Biologic behavior in breast invasive Ductal Carcinoma. Clin Breast Cancer. 2018;18:e335–44.CrossRefPubMed
15.
go back to reference Bove S, Comes MC, Lorusso V, Cristofaro C, Didonna V, Gatta G, et al. A ultrasound-based radiomic approach to predict the nodal status in clinically negative breast cancer patients. Sci Rep. 2022;12:7914.CrossRefPubMedPubMedCentral Bove S, Comes MC, Lorusso V, Cristofaro C, Didonna V, Gatta G, et al. A ultrasound-based radiomic approach to predict the nodal status in clinically negative breast cancer patients. Sci Rep. 2022;12:7914.CrossRefPubMedPubMedCentral
16.
go back to reference Liu Z, Wang S, Dong D, Wei J, Fang C, Zhou X, et al. The applications of Radiomics in Precision diagnosis and treatment of Oncology: Opportunities and Challenges. Theranostics. 2019;9:1303–22.CrossRefPubMedPubMedCentral Liu Z, Wang S, Dong D, Wei J, Fang C, Zhou X, et al. The applications of Radiomics in Precision diagnosis and treatment of Oncology: Opportunities and Challenges. Theranostics. 2019;9:1303–22.CrossRefPubMedPubMedCentral
17.
go back to reference Mao N, Yin P, Wang Q, Liu M, Dong J, Zhang X, et al. Added Value of Radiomics on Mammography for breast Cancer diagnosis: a feasibility study. J Am Coll Radiol JACR. 2019;16(4 Pt A):485–91.CrossRefPubMed Mao N, Yin P, Wang Q, Liu M, Dong J, Zhang X, et al. Added Value of Radiomics on Mammography for breast Cancer diagnosis: a feasibility study. J Am Coll Radiol JACR. 2019;16(4 Pt A):485–91.CrossRefPubMed
18.
go back to reference Parikh J, Selmi M, Charles-Edwards G, Glendenning J, Ganeshan B, Verma H, et al. Changes in primary breast cancer heterogeneity may augment midtreatment MR imaging assessment of response to neoadjuvant chemotherapy. Radiology. 2014;272:100–12.CrossRefPubMed Parikh J, Selmi M, Charles-Edwards G, Glendenning J, Ganeshan B, Verma H, et al. Changes in primary breast cancer heterogeneity may augment midtreatment MR imaging assessment of response to neoadjuvant chemotherapy. Radiology. 2014;272:100–12.CrossRefPubMed
19.
go back to reference Gao Y, Luo Y, Zhao C, Xiao M, Ma L, Li W, et al. Nomogram based on radiomics analysis of primary breast cancer ultrasound images: prediction of axillary lymph node tumor burden in patients. Eur Radiol. 2021;31:928–37.CrossRefPubMed Gao Y, Luo Y, Zhao C, Xiao M, Ma L, Li W, et al. Nomogram based on radiomics analysis of primary breast cancer ultrasound images: prediction of axillary lymph node tumor burden in patients. Eur Radiol. 2021;31:928–37.CrossRefPubMed
20.
go back to reference Chawla NV, Bowyer KW, Hall LO, Kegelmeyer WP. SMOTE: synthetic minority over-sampling technique. J Artif Intell Res. 2002;16:321–57.CrossRef Chawla NV, Bowyer KW, Hall LO, Kegelmeyer WP. SMOTE: synthetic minority over-sampling technique. J Artif Intell Res. 2002;16:321–57.CrossRef
21.
go back to reference Welch BL. The generalisation of student’s problems when several different population variances are involved. Biometrika. 1947;34:28–35.PubMed Welch BL. The generalisation of student’s problems when several different population variances are involved. Biometrika. 1947;34:28–35.PubMed
22.
go back to reference Fisher -. ON THE INTERPRETATION OF X2 FROM CONTINGENCY TABLE.pdf. Fisher -. ON THE INTERPRETATION OF X2 FROM CONTINGENCY TABLE.pdf.
23.
go back to reference Akrami M, Meshksar A, Ghoddusi JM, Safarpour MM, Tahmasebi S, Zangouri V, et al. Prognostic role of Lymphovascular Invasion in patients with early breast Cancer. Indian J Surg Oncol. 2021;12:671–7.CrossRefPubMedPubMedCentral Akrami M, Meshksar A, Ghoddusi JM, Safarpour MM, Tahmasebi S, Zangouri V, et al. Prognostic role of Lymphovascular Invasion in patients with early breast Cancer. Indian J Surg Oncol. 2021;12:671–7.CrossRefPubMedPubMedCentral
24.
go back to reference Gujam FJA, Going JJ, Edwards J, Mohammed ZMA, McMillan DC. The role of lymphatic and blood vessel invasion in predicting survival and methods of detection in patients with primary operable breast cancer. Crit Rev Oncol Hematol. 2014;89:231–41.CrossRefPubMed Gujam FJA, Going JJ, Edwards J, Mohammed ZMA, McMillan DC. The role of lymphatic and blood vessel invasion in predicting survival and methods of detection in patients with primary operable breast cancer. Crit Rev Oncol Hematol. 2014;89:231–41.CrossRefPubMed
25.
go back to reference Zhao Y, Yang N, Wang X, Huang Y, Zhou X, Zhang D. Potential roles of lymphovascular space invasion based on tumor characteristics provide important prognostic information in T1 tumors with ER and HER2 positive breast cancer. Clin Transl Oncol off Publ Fed Span Oncol Soc Natl Cancer Inst Mex. 2020;22:2275–85. Zhao Y, Yang N, Wang X, Huang Y, Zhou X, Zhang D. Potential roles of lymphovascular space invasion based on tumor characteristics provide important prognostic information in T1 tumors with ER and HER2 positive breast cancer. Clin Transl Oncol off Publ Fed Span Oncol Soc Natl Cancer Inst Mex. 2020;22:2275–85.
Metadata
Title
Automated breast volume scanner based Radiomics for non-invasively prediction of lymphovascular invasion status in breast cancer
Authors
Yue Li
Xiaomin Wu
Yueqiong Yan
Ping Zhou
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11336-w

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine